Antitumor activity of patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells: In vitro results and cli

Primary tabs

Average: 7 (1 vote)
Number of included patients: 
Therapeutic intervention: 

Background: Renal cell carcinoma (RCC) has been shown to be highly susceptible to immune-based treatment strategies.
In the present study, patient-derived tumor cells were fused with
allogeneic dendritic cells (DC) to elicit antitumor activity against
RCC. DC from HLA-A2+ healthy donors were fused with primary RCC cells
from 10 patients. Phenotype of fusion cells was characterized by flow
cytometer and confocal microscopy. In vitro, T-cell proliferation,
IFN-? secretion, and cytotocic T lymphocytes (CTL) activity elicited by
allogeneic DC/RCC fusion cells were assessed. Clinically, 10 patients
were vaccinated with allogeneic DC/RCC fusion vaccine. The adverse
effects and toxicity were observed. The clinical response was evaluated
by CT scans.
Results: After fusion, the created hybrids
expressed both tumor-associated antigen and DC-derived molecules and
could stimulate the proliferation and IFN-? secretion of T-cells as
well as elicit strong CTL activity against RCC cells in vitro. In vivo, neither
serious adverse effects nor signs of autoimmune disease were observed
after vaccination therapy. Percentage of T lymphocyte subsets in
peripheral blood of patients was increased significantly. One of 10
patients exhibited a partial response with regression of lung
metastases. Six patients showed stable disease with stabilization of
previously progressive disease (follow-up 1.5 year).
Conclusions: The data suggest that allogeneic DC/RCC fusion vaccine is safe and can elicit immunological responses in patients with RCC.